Laval, Canada
Laval, Canada

Time filter

Source Type

Martineau E.,University of Ottawa | Martineau E.,BELLUS Health Inc. | de Guzman J.M.,BELLUS Health Inc. | Rodionova L.,BELLUS Health Inc. | And 3 more authors.
Journal of the American Society for Mass Spectrometry | Year: 2010

This paper describes an efficient and reproducible screening method for identifying low molecular weight compounds that bind to amyloid β peptides (Aβ) peptides using electrospray ionization mass spectrometry (ESI-MS). Low molecular weight compounds capable of interacting with soluble Aβ may be able to modulate/inhibit the Aβ aggregation process and serve as potential disease-modifying agents for AD. The present approach was used to rank the binding affinity of a library of compounds to Aβ1-40 peptide. The results obtained show that low molecular weight compounds bind similarly to Aβ1-42, Aβ1-40, as well as Aβ1-28 peptides and they underline the critical role of Aβ peptide charge motif in binding at physiological pH. Finally, some elements of structure-activity relationship (SAR) involved in the binding affinity of homotaurine to soluble Aβ peptides are discussed. © 2010.


Aisen P.S.,University of California at San Diego | Gauthier S.,ll Center for Studies in Aging | Ferris S.H.,New York University | Ferris S.H.,Nathan Kline Institute | And 9 more authors.
Archives of Medical Science | Year: 2011

Introduction: The aim of the study was to assess the clinical efficacy, safety, and disease-modification effects of tramiprosate (homotaurine, ALZHEMED™) in mild-to-moderate Alzheimer's disease (AD). Material and methods: Double-blind, placebo-controlled, randomized trial in 67 clinical centres across North America. Patients aged ≥ 50 years, with mild-to-moderate AD (Mini-Mental State Examination score between 16 and 26) and on stable doses of cholinesterase inhibitors, alone or with memantine. Intervention: 78-week treatment with placebo, tramiprosate 100 mg or tramiprosate 150 mg BID. Measurements: Alzheimer Disease Assessment Scale - cognitive subscale (ADAS-cog) and Clinical Dementia Rating - Sum of Boxes (CDR-SB) assessments were performed at baseline and every 13 weeks. Baseline and 78-week magnetic resonance imaging (MRI) hippocampus volume (HV) measurements were conducted in a subgroup of patients. Results: A total of 1,052 patients were enrolled and 790 (75.1%) completed the 78-week trial. Patient discontinuation and reasons for withdrawal were similar across groups. Planned analyses did not reveal statistically significant between-group differences. Lack of adequate statistical validity of the planned analysis models led to the development of revised predictive models. These adjusted models showed a trend toward a treatment effect for ADAS-cog (P = 0.098) and indicated significantly less HV loss for tramiprosate 100 mg (P = 0.035) and 150 mg (P = 0.009) compared to placebo. The incidence of adverse events was similar across treatment groups. Conclusions: The primary planned analyses did not show a significant treatment effect, but were confounded by unexplained variance. Post-hoc analyses showed a significant treatment-related reduction in HV loss. However, there was only a trend towards slowing of decline on the ADAS-cog and no slowing of decline on the CDR-SB. These results must be interpreted in consideration of the limitations of clinical and disease-modification outcome measures and their relationship, the heterogeneity of the disease and the impact of confounding demographic and clinical variables. Copyright © 2011 Termedia & Banach.


The invention relates to methods, compounds, and compositions for delivering 1,3-propanedisulfonic acid (1,3PDS) in a subject, preferably a human subject. The invention encompasses compounds that will yield or generate 1,3PDS, either in vitro or in vivo. The invention also relates to sulfonate ester prodrugs of 1,3PDS as well as Gemini dimmers and oligomers of 1,3PDS for the prevention or treatment of associated diseases and conditions.


Patent
BELLUS Health Inc. | Date: 2011-09-20

Methods, compounds, pharmaceutical compositions and kits are described for treating or preventing amyloid-related disease.


LONDON, UK / ACCESSWIRE / February 27, 2017 / Active Wall St. announces the list of stocks for today's research reports. Pre-market the Active Wall St. team provides the technical coverage impacting selected stocks trading on the Toronto Exchange and belonging under the Biotechnology industry. Companies recently under review include Oncolytics Biotech, BELLUS Health, Emerald Health Therapeutics, and OrganiGram Holdings. Get all of our free research reports by signing up at: On Friday, February 24, 2017, the Toronto Exchange Composite Index was down 1.57%, finishing the day at 15,533.47. The TSX Venture Composite Index, on the other hand, closed at 836.27, down 0.38%. The Healthcare Index was also in the red, closing the day at 74.08, down 2.31%. Active Wall St. has initiated research reports on the following equities: Oncolytics Biotech Inc. (TSX: ONC), BELLUS Health Inc. (TSX: BLU), Emerald Health Therapeutics Inc. (TSX-V: EMH), and OrganiGram Holdings Inc. (TSX-V: OGI). Register with us now for your free membership and research reports at: Calgary, Canada headquartered Oncolytics Biotech Inc.'s stock fell 5.13%, to finish Friday's session at $0.37 with a total volume of 203,121 shares traded. Over the last one month and the previous three months, Oncolytics Biotech's shares have surged 37.04% and 68.18%, respectively. Shares of the Company, which focuses on the discovery and development of pharmaceutical products for the treatment of cancers, are trading above its 50-day and 200-day moving averages. See our research report on ONC.TO at: On Friday, shares in Laval, Canada-based BELLUS Health Inc. recorded a trading volume of 261,020 shares, which was higher than their three months average volume of 55,040 shares. The stock ended the day 3.85% lower at $0.25. BELLUS Health's stock has advanced 4.17% in the past three months. Shares of the Company, which together with its subsidiaries, focuses on the research and development of drugs for rare diseases, are trading below its 50-day moving average of $0.27. The complimentary research report on BLU.TO at: On Friday, shares in Victoria, Canada headquartered Emerald Health Therapeutics Inc. ended the session 1.45% lower at $1.36 with a total volume of 906,734 shares traded. Emerald Health Therapeutics' shares have surged 724.24% in the past one year. Shares of the Company, which together with its subsidiaries, produces and sells medical marijuana in Canada, are trading above its 200-day moving average. Further, the stock's 50-day moving average of $1.43 is greater than its 200-day moving average of $1.01. Register for free and access the latest research report on EMH.V at: Moncton, Canada-based OrganiGram Holdings Inc.'s stock closed the day 1.89% lower at $2.60. The stock recorded a trading volume of 811,924 shares. OrganiGram's shares have rallied 242.11% in the previous one year. The company's shares are trading above their 200-day moving average. Moreover, the stock's 50-day moving average of $2.71 is greater than its 200-day moving average of $2.50. Shares of the Company, which through its subsidiary, Organigram Inc., produces and sells medical marijuana in Canada, are trading at a PE ratio of 650.00. Get free access to your research report on OGI.V at: Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. AWS has not been compensated; directly or indirectly; for producing or publishing this document. The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst, for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way. AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/. For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.


LONDON, UK / ACCESSWIRE / February 27, 2017 / Active Wall St. announces the list of stocks for today's research reports. Pre-market the Active Wall St. team provides the technical coverage impacting selected stocks trading on the Toronto Exchange and belonging under the Biotechnology industry. Companies recently under review include Oncolytics Biotech, BELLUS Health, Emerald Health Therapeutics, and OrganiGram Holdings. Get all of our free research reports by signing up at: On Friday, February 24, 2017, the Toronto Exchange Composite Index was down 1.57%, finishing the day at 15,533.47. The TSX Venture Composite Index, on the other hand, closed at 836.27, down 0.38%. The Healthcare Index was also in the red, closing the day at 74.08, down 2.31%. Active Wall St. has initiated research reports on the following equities: Oncolytics Biotech Inc. (TSX: ONC), BELLUS Health Inc. (TSX: BLU), Emerald Health Therapeutics Inc. (TSX-V: EMH), and OrganiGram Holdings Inc. (TSX-V: OGI). Register with us now for your free membership and research reports at: Calgary, Canada headquartered Oncolytics Biotech Inc.'s stock fell 5.13%, to finish Friday's session at $0.37 with a total volume of 203,121 shares traded. Over the last one month and the previous three months, Oncolytics Biotech's shares have surged 37.04% and 68.18%, respectively. Shares of the Company, which focuses on the discovery and development of pharmaceutical products for the treatment of cancers, are trading above its 50-day and 200-day moving averages. See our research report on ONC.TO at: On Friday, shares in Laval, Canada-based BELLUS Health Inc. recorded a trading volume of 261,020 shares, which was higher than their three months average volume of 55,040 shares. The stock ended the day 3.85% lower at $0.25. BELLUS Health's stock has advanced 4.17% in the past three months. Shares of the Company, which together with its subsidiaries, focuses on the research and development of drugs for rare diseases, are trading below its 50-day moving average of $0.27. The complimentary research report on BLU.TO at: On Friday, shares in Victoria, Canada headquartered Emerald Health Therapeutics Inc. ended the session 1.45% lower at $1.36 with a total volume of 906,734 shares traded. Emerald Health Therapeutics' shares have surged 724.24% in the past one year. Shares of the Company, which together with its subsidiaries, produces and sells medical marijuana in Canada, are trading above its 200-day moving average. Further, the stock's 50-day moving average of $1.43 is greater than its 200-day moving average of $1.01. Register for free and access the latest research report on EMH.V at: Moncton, Canada-based OrganiGram Holdings Inc.'s stock closed the day 1.89% lower at $2.60. The stock recorded a trading volume of 811,924 shares. OrganiGram's shares have rallied 242.11% in the previous one year. The company's shares are trading above their 200-day moving average. Moreover, the stock's 50-day moving average of $2.71 is greater than its 200-day moving average of $2.50. Shares of the Company, which through its subsidiary, Organigram Inc., produces and sells medical marijuana in Canada, are trading at a PE ratio of 650.00. Get free access to your research report on OGI.V at: Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. AWS has not been compensated; directly or indirectly; for producing or publishing this document. The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst, for further information on analyst credentials, please email info@activewallst.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way. AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/. For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute. LONDON, UK / ACCESSWIRE / February 27, 2017 / Active Wall St. announces the list of stocks for today's research reports. Pre-market the Active Wall St. team provides the technical coverage impacting selected stocks trading on the Toronto Exchange and belonging under the Biotechnology industry. Companies recently under review include Oncolytics Biotech, BELLUS Health, Emerald Health Therapeutics, and OrganiGram Holdings. Get all of our free research reports by signing up at: On Friday, February 24, 2017, the Toronto Exchange Composite Index was down 1.57%, finishing the day at 15,533.47. The TSX Venture Composite Index, on the other hand, closed at 836.27, down 0.38%. The Healthcare Index was also in the red, closing the day at 74.08, down 2.31%. Active Wall St. has initiated research reports on the following equities: Oncolytics Biotech Inc. (TSX: ONC), BELLUS Health Inc. (TSX: BLU), Emerald Health Therapeutics Inc. (TSX-V: EMH), and OrganiGram Holdings Inc. (TSX-V: OGI). Register with us now for your free membership and research reports at: Calgary, Canada headquartered Oncolytics Biotech Inc.'s stock fell 5.13%, to finish Friday's session at $0.37 with a total volume of 203,121 shares traded. Over the last one month and the previous three months, Oncolytics Biotech's shares have surged 37.04% and 68.18%, respectively. Shares of the Company, which focuses on the discovery and development of pharmaceutical products for the treatment of cancers, are trading above its 50-day and 200-day moving averages. See our research report on ONC.TO at: On Friday, shares in Laval, Canada-based BELLUS Health Inc. recorded a trading volume of 261,020 shares, which was higher than their three months average volume of 55,040 shares. The stock ended the day 3.85% lower at $0.25. BELLUS Health's stock has advanced 4.17% in the past three months. Shares of the Company, which together with its subsidiaries, focuses on the research and development of drugs for rare diseases, are trading below its 50-day moving average of $0.27. The complimentary research report on BLU.TO at: On Friday, shares in Victoria, Canada headquartered Emerald Health Therapeutics Inc. ended the session 1.45% lower at $1.36 with a total volume of 906,734 shares traded. Emerald Health Therapeutics' shares have surged 724.24% in the past one year. Shares of the Company, which together with its subsidiaries, produces and sells medical marijuana in Canada, are trading above its 200-day moving average. Further, the stock's 50-day moving average of $1.43 is greater than its 200-day moving average of $1.01. Register for free and access the latest research report on EMH.V at: Moncton, Canada-based OrganiGram Holdings Inc.'s stock closed the day 1.89% lower at $2.60. The stock recorded a trading volume of 811,924 shares. OrganiGram's shares have rallied 242.11% in the previous one year. The company's shares are trading above their 200-day moving average. Moreover, the stock's 50-day moving average of $2.71 is greater than its 200-day moving average of $2.50. Shares of the Company, which through its subsidiary, Organigram Inc., produces and sells medical marijuana in Canada, are trading at a PE ratio of 650.00. Get free access to your research report on OGI.V at: Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. AWS has not been compensated; directly or indirectly; for producing or publishing this document. The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst, for further information on analyst credentials, please email info@activewallst.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way. AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/. For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

Loading BELLUS Health Inc. collaborators
Loading BELLUS Health Inc. collaborators